TheraRadar
← Back
Data updated: Jul 17, 2026

rEVO Biologics, Inc.

Biotech
Pharmaceuticals

rEVO Biologics, Inc. is a biotechnology company with 1 FDA-approved products.

2009
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

rEVO Biologics, Inc.'s Key Drugs

rEVO Biologics, Inc.'s key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

rEVO Biologics, Inc.'s Recent FDA Approvals

New NDA/BLA approvals for rEVO Biologics, Inc. over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

rEVO Biologics, Inc.'s Therapeutic Areas

Disease areas where rEVO Biologics, Inc. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

rEVO Biologics, Inc. Pipeline Snapshot

Active clinical trials for rEVO Biologics, Inc. across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling